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Rhabdomyosarcoma is a soft tissue sarcoma arising from cells of a mesenchymal or skeletal muscle lineage. Alveolar
rhabdomyosarcoma (ARMS) is more aggressive than the more common embryonal (ERMS) subtype. ARMS is more
prone to metastasis and carries a poorer prognosis. In contrast to ERMS, the majority of ARMS tumors carry one of
several characteristic chromosomal translocations, such as t(2;13)(q35;q14), which results in the expression of a
PAX3-FOXO1 fusion transcription factor. In this review we discuss the genes that cooperate with PAX3-FOXO1, as well
as the target genes of the fusion transcription factor that contribute to various aspects of ARMS tumorigenesis. The
characterization of these pathways will lead to a better understanding of ARMS tumorigenesis and will allow the
design of novel targeted therapies that will lead to better treatment for this aggressive pediatric tumor.
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According to the American Cancer Society, rhabdomyo-
sarcoma (RMS) comprises about three percent of child-
hood cancers, with about 350 new cases occurring
annually in the US [1], and it affects slightly more males
than females [2]. RMS is a small, round, blue cell tumor
usually arising in skeletal muscle tissue, and it is thought
to originate from mesenchymal cells likely committed to
the skeletal muscle lineage. Consistent with a myogenic
origin, RMS tumors express skeletal muscle markers such
as skeletal muscle actin and myosin, desmin, myoglobin,
Z-band protein, MYOD and often myogenin [3-7]. RMS
consists of two major histological subtypes, embryonal
and alveolar RMS. The embryonal subtype (ERMS) is
thought to be histologically reminiscent of embryonic
developing skeletal muscle [7]. ERMS is the most preva-
lent of the subtypes, accounting for about 60% of RMS
cases [2]. It occurs mainly in children younger than 10
years and is usually associated with a favorable prognosis,
with a failure-free survival rate of 81% [8,9]. Tumors usu-
ally localize to the head and neck (including the extraocu-
lar muscles of the eye), the genitourinary tract and the* Correspondence: gerard.grosveld@stjude.org
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distribution, and reproduction in any mediumretroperitoneum [7,8]. The alveolar subtype (ARMS) con-
stitutes approximately another 20% of RMS cases [10] and
occurs predominantly in adolescents. Histologically,
ARMS tumors typically contain alveoli structures similar
in appearance to those seen in the lung [7], though solid-
variant ARMS does occur [11]. Primary ARMS tumors
typically arise in the extremities and trunk [7-9,12], and
they are more aggressive than their ERMS counterparts.
ARMS is associated with a poorer prognosis, with a 5-year
failure-free survival of 65% [8].
A characteristic of the ARMS subtype is the occurrence
of recurrent chromosomal translocations. The most com-
mon of these is t(2;13)(q35;q14), which results in the
expression of an oncogenic fusion protein. This fusion
protein consists of the paired and homeodomains of the
PAX3 transcription factor with the potent transcriptional
activation domain of FOXO1 (FKHR), a member of the
forkhead (FOX) family of transcription factors [13-15].
The PAX3 homeodomain is required to recapitulate
PAX3-FOXO1-induced tumorigenesis, though the paired
domain may play a minor role [16,17]. The PAX3-FOXO1
fusion protein can be detected in about 55% of ARMS
cases [18]. A similar translocation of t(1;13)(p36;q14) fuses
the PAX7 DNA-binding domains, the closest homolog of
PAX3, to FOXO1 [19]. This translocation occurs in a fur-
ther 22% of ARMS cases [18]. Recently, further similard Central Ltd. This is an Open Access article distributed under the terms of the
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t(2;X)(q35;q13), which results in PAX3-AFX fusion [20],
and t(2;2)(q35;p23) and t(2;8)(q35;q13), which generate a
fusion protein of PAX3-NCOA1 and PAX3-NCOA2,
respectively [21,22]. These “cryptic” rare fusion variants
are thought to be present in up to another 10% of ARMS
tumors [7]. During normal development, PAX3 expression
occurs in the neural tube and dermomyotome [23], and it
is required for the normal migration of skeletal muscle
precursors to the limb bud [24]. PAX7 expression is a
marker of satellite cells in adult skeletal muscle [25] and is
required for normal self-renewal [26]. Unlike skeletal
muscle-specific PAX3 and PAX7, FOXO1A, AFX,
NCOA1 and NCOA2 are widely expressed and mediate
gene transcription downstream of cell signaling pathways
[27-31]. All of the ARMS fusion proteins consist of the
PAX3/7 DNA-binding domains fused to the transcrip-
tional activation domains of more potent transcription fac-
tors (see Figure 1) [14,15,22]. Genome-wide transcription
factor-binding studies have not yet been performed to de-
termine whether wild-type PAX3 and PAX7-binding sites
differ from these PAX3/7 fusion transcription factor-
binding sites.
Expression of these ARMS fusion transcription factors is
thought to abrogate normal skeletal muscle differentiation,
allowing aberrant cell division and tumor development.
PAX3 expression can inhibit myogenic differentiation of
cultured myoblasts [35]. Although PAX3 protein is rapidly
degraded during early myogenic differentiation, PAX3-
FOXO1 has a significantly longer half-life than wild-type
PAX3 [36]. PAX3/7-FOXO1 is capable of suppressing
MyoD expression and activity [37,38]. PAX7-FOXO1 ex-
pression induces NFκB signaling, which inhibits myogen-
esis via activation of cyclin D1/CDK4 complexes. These
complexes sequester MyoD, which would normally drive
cell cycle withdrawal and myogenic differentiation [39]. In
addition transcriptionally inactive MyoD can enhanceFigure 1 Gene translocation in alveolar rhabdomyosarcoma. Scale dia
arising from chromosomal translocations occurring in ARMS. Green or yello
are indicated in like colors. DNA-binding domains are indicated as: paired d
and basic helix-loop-helix domain (bHLH). Regions of the proteins known t
domains include the octapeptide domain (O), PAS domains (PAS A/B), LXX
derived from the following references: [14,19-22,32-34].PAX3-FOXO1 transcriptional activity [37]. There is also
evidence that MyoD transcriptional activity is abrogated in
ERMS tumors [40].
The remaining ARMS tumors are classed as fusion-
negative ARMS. However, fusion-negative ARMS are in-
distinguishable on the levels of gene expression and in
clinical outcome from ERMS tumors, leading some to
argue that translocation status should be the defining
factor of ARMS [41-44]. Within the ARMS subtype,
prognosis can vary by disease stage at diagnosis as well
as translocation status. For example, patients presenting
with metastatic disease have an estimated 4-year overall
survival rate of 75% for PAX7-FOXO1, while those with
the PAX3-FOXO1 translocation have only 8% estimated
4-year overall survival [18]. Indeed, there is evidence
that the PAX3-FOXO1 is a more potent oncogene than
PAX7-FOXO1. Barr et al. [45] found that only 1/24
PAX3-FOXO1-positive ARMS tumors had amplification
of the PAX3-FOXO1 gene, while PAX7-FOXO1 was
amplified in 10/11 PAX7-FOXO1 ARMS, implying that
genomic amplification of PAX7-FOXO1 is required for
tumorigenesis, while a single copy of PAX3-FOXO1 is
sufficient. However the gene expression profiles of
PAX3-FOXO1- and PAX7-FOXO1-expressing tumors
have not, to the author’s knowledge, been specifically
compared to identify the gene set responsible for this
difference in prognosis between ARMS tumors with
these two fusion genes.
Review
PAX3-FOXO1 is the most common fusion gene in
ARMS. This fusion transcription factor is thought to
drive the gene expression that causes the worse progno-
sis in ARMS tumors. Many studies have sought to iden-
tify the differences in gene expression between ERMS
and ARMS, as well as the genes aberrantly regulated by
PAX3-FOXO1. In this review, we summarize these genegram showing the parent proteins and the resulting fusion proteins
w indicates the protein fusion sites [14,19-22]. Homologous domains
omain (PD), homeodomain (HD), fork head DNA-binding domain (FH)
o act as transcriptional activation domains are indicated (TAD). Other
LL motifs (L1-L7) and glutamine-rich region (Q-rich). Maps were
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and/or ARMS. Moreover, we consolidate these data into
a list of genes that may well represent the means by
which ARMS tumors obtain a more aggressive pheno-
type than ERMS.Cooperating mutations in ARMS tumors
It is likely that PAX3/7-FOXO1 translocation is one of
the earliest events in ARMS tumorigenesis as it occurs
in the majority of ARMS cases, more often than any
other genetic lesion characterized in the disease. How-
ever, PAX3-FOXO1 expression in normal cells is not
sufficient to induce transformation, and other genetic
alterations are required [46-48]. Genomic amplification
is common in ARMS tumors. The three most common
amplifications seen in ARMS involve regions of chromo-
somes 2, 12 and 13 [49].
The region of chromosome 12 amplification spans
12q13-15 and is reported in 28% to 56% of ARMS
tumors [49-52]. This 12q13-15 region includes genes
such as C/EBP-homolog and transcription factor CHOP/
DDIT3/GADD153, sarcoma-amplified sequence and
transmembrane 4 superfamily member SAS/TSPAN31,
alpha 2-macroglobulin receptor A2MR/LRP1, Sonic
hedgehog (SHH) pathway effector and zinc finger tran-
scription factor GLI1, cyclin-dependent kinase cell cycle
regulator CDK4 and p53 pathway modulator MDM2. In
most cases, gene amplification accompanies an increase
in gene expression [50,53].
Though GLI1 is amplified genetically, the expression
of this gene is not always associated with its genetic
amplification. When GLI1 is overexpressed in RMS, it
has been associated with an undifferentiated subtype ra-
ther than ERMS or ARMS, indicating that GLI1 may
play a role in tumors that show primitive histopatho-
logical features [54]. Thus, GLI1 overexpression cannot
be well associated with the ARMS pathology.
MDM2 is perhaps the best candidate oncogene in this re-
gion because of its inhibitory effect on p53 function [55].
However, MDM2 is not always included in this 12q13-15
amplification. RH30, an ARMS cell line, lacks amplification
of MDM2 but shows amplification and overexpression of
SAS, CHOP, GLI1 and A2MR [53]. In addition, the fre-
quency of MDM2 gene amplification specifically may be as
low as 10% in ARMS tumors [56]. One study found only 2
of 34 ARMS samples to be highly immunoreactive for
MDM2 [12]. Moreover, MDM2 expression shows no asso-
ciation with patient prognosis or other clinicopathologic
parameters [12]. Thus, it may be amplification of one of the
other genes at this chromosome 12 locus that is the import-
ant cooperating mutation with PAX3-FOXO1.
Other alterations in the p53 pathway have been found
in ARMS. In ARMS tumor samples mutated p53 wasreported in 0 to 22% of cases [12,56,57]. RMS cell lines
show a significantly higher rate of p53 abnormalities
with 60%, indicating establishment of these cell lines
through xenograft and cell culture increases the propor-
tion of cell lines with p53 alterations [56]. Looking at
p53 and MDM2 expression levels, both are low in
ARMS and ERMS. Metastatic ERMS tumors show sig-
nificantly higher p53 protein expression, indicating that
p53 gene alterations are a late event in rhabdomyosarco-
magenesis. Again, p53 status did not show any correl-
ation to prognosis [58].
Chromosome 2 has been shown to be amplified at
2p24 in 32 to 60% of ARMS tumors [49,51,59,60]. This
region is known to contain the proto-oncogene N-MYC.
Two independent studies have shown that a gain in the
genomic copy number of the N-MYC gene is associated
with an unfavorable disease outcome [59,61]. In
addition, N-MYC is more highly expressed in ARMS
cells lines than ERMS lines, despite the fact that it was
found to only be genomically amplified in one of the five
lines, indicating more than one mechanism of N-MYC
overexpression in ARMS. However, in this study no clear
relationship in N-MYC expression was seen with regard
to primary tumor samples [62].
Another chromosomal region frequently amplified in
ARMS is 13q31-32, showing amplification in between 14
and 19% of ARMS tumors [49,51]. Presence of this amp-
lification is significantly associated with poorer failure-
free survival in ARMS [63]. The minimum overlapping
region of amplification at this region was originally
defined as only containing two genes: GPC5 and
C13ORF25. The C12ORF25 gene encodes the micro-
RNA cluster miR-17-92 (MIR17HG) in an intron [64].
GPC5 overexpression can increase cell proliferation
through the modulation of the growth factor activity of
FGF2, HGF and WNT1a [64]. However, more thorough
mapping of the genetic amplification showed that the
entire GPC5 locus was only amplified in 12.5% of 13q31
amplified ARMS tumors, while the minimally amplified
region contains only the peptidylprolyl isomerase
pseudogene (LOC390419) and MIR17HG. This amplifi-
cation is particularly prevalent in PAX7-FOXO1-positive
ARMS tumors. The miR-17-92 cluster of micro-RNAs
has been shown to play a role in a variety of cancer types
(for review, see [65]). In PAX7-FOXO1, but not PAX3-
FOXO1 expressing ARMS, overexpression of miR-17,
-19a, -19b, 20a and 92a is specifically associated with an
increased rate of 2-year treatment failure. This indicates
a possible pro-tumorigenic interaction between PAX7-
FOXO1 and miR-17-92 locus overexpression [63].
Rhabdomyosarcoma can also be associated with a loss
of heterozygosity (LOH) or loss of imprinting (LOI) at
11p15.5 [66,67]. This region contains several imprinted
genes such as IGF2, which is maternally imprinted
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which are paternally imprinted (maternal allele is
expressed) [68-70]. IGF2 expression appears to be spe-
cifically upregulated by changes in imprinting or LOH at
this locus in RMS. ERMS tumors are associated predom-
inantly with a LOH at the IGF2 locus, though there is
some discrepancy in the proportion of ERMS tumors
showing this change: 23% according to Anderson et al.
[66] and 72% according to Visser et al. [67]. Conversely,
IGF2 is upregulated by LOI in 46% of fusion-positive
ARMS tumors, while imprinting of H19 is conserved in
93% [66]. This indicates that an increase in IGF2 expres-
sion in RMS is important for tumorigenesis, though the
mechanism of this upregulation, either LOH or LOI,
varies by subtype.
A screen for PAX3-FOXO1-interacting proteins using
ARF−/− primary mouse myoblasts expressing PAX3-
FOXO1 and an RH30 cDNA expression library identi-
fied a gene that could induce tumor formation where
ARF−/− myoblasts expressing PAX3-FOXO1 alone did
not. The RH30 gene expression library expressed a trun-
cated fragment of this novel gene dubbed IRIZIO, and
expression of either this truncated form or the full-
length wild-type IRIZIO were protumorigenic in this
model [71]. Due to the nature of the screen, and given
that abrogation of the p53 and pRb pathways are
required for PAX3-FOXO1-driven cell transformation
[46,47], this screen was expected to identify proteins that
could abrogate the pRb pathway [71]. The mechanism of
the interaction between IRIZIO and pRb, however, has
yet to be identified.
PAX3-FOXO1 target genes
Many gene expression studies have been performed by
various groups to try to identify genes that are either
downstream of PAX3-FOXO1 gene expression in vari-
ous cell types or are indicative of ARMS tumor gene
expression profiles (see Table 1). Only a small propor-
tion of these studies have gone on to further investigate
the mechanism of PAX3-FOXO1 regulation of these
genes and/or what role these genes may play in ARMS
tumorigenesis.
Two of these genes have already been mentioned as
cooperating mutations seen in ARMS tumors, N-MYC
and IGF2. The N-MYC locus is known to be amplified
in a proportion of ARMS tumors, and the IGF2 locus is
known to show LOI in ARMS tumors (see cooperating
mutations in ARMS tumors). However, these studies
also indicate that PAX3-FOXO1 may regulate the gene
expression from these loci.
N-MYC expression has been shown to be upregulated
in four independent studies using PAX3-FOXO1 target-
ing siRNA in the ARMS cell line, RH4 [72], PAX3-
FOXO1 overexpression in the RD (ERMS) cell line[73,81] and in ARMS versus non ARMS tumor cell lines
[78]. A tamoxifen (4-OHT)-inducible PAX3-FOXO1-ER
construct induced upregulation of both N-MYC mRNA
and protein in the transduced ERMS cell line, RD, and
this was not sensitive to cycloheximide treatment, indi-
cating that N-MYC is a direct transcriptional target of
PAX3-FOXO1. However the PAX3-FOXO1 regulatory
region for N-MYC did not appear to be contained within
−1871 to +1058 of the N-MYC gene. Consistent with a
transforming role for both PAX3-FOXO1 and N-MYC,
the two genes synergized in soft agar colony-forming
assays [81]. In addition, knockdown of N-MYC expres-
sion identified a positive feedback loop between N-MYC
and PAX3-FOXO1 [93].
IGF2 was shown to be specifically overexpressed in
ARMS compared to Ewing’s sarcoma cell lines [75],
which is perhaps not surprising given that LOI of the
IGF2 is seen in almost half of ARMS tumors [66]. How-
ever, Khan et al. [5] have shown that, in NIH3T3 cells,
PAX3-FOXO1 expression can induce the upregulation
of IGF2 mRNA. Interestingly, H19 expression was also
found to be upregulated in response to PAX3-FOXO1
expression in these cells. Khan et al. [5] did not investi-
gate whether PAX3-FOXO1 can regulate imprinting of
this locus, and the mechanism of PAX3-FOXO1 regula-
tion of IGF2 mRNA expression remains unknown.
Two factors shown to be upregulated in PAX3-
FOXO1-expressing cells, MET [73,81,90,91] and CXCR4
[85,86], are thought to play a role in the increased pro-
pensity for metastasis seen with ARMS.
MET is the receptor for hepatocyte growth factor/scatter
factor (HGF/SF) [94]. HGF-MET signaling has been shown
to play an important role in both normal skeletal muscle
development and regeneration, and it is involved in regu-
lating myogenic cell migration, survival, proliferation and
differentiation [95,96]. MET appears to be a downstream
target of PAX3. Splotch mice, which express a mutant
PAX3 and fail to form limb muscles because of an inhib-
ition of myogenic precursor cell migration, show a
decreased expression of MET [24,97]. MET has also been
found in five independent studies to be downstream of the
PAX3-FOXO1 fusion protein in ARMS [73,81,90-92].
However, in the case of ARMS, it appears that HGF may
play a role in chemoattraction of tumor cells to the bone
marrow, which is a common site of metastasis in ARMS
cases [98,99]. ARMS cell line CW9019 shows chemotaxis
toward bone marrow-derived-fibroblast-conditioned media
in vitro, and this migration is inhibited by the MET-
blocking agent, K-252a. Moreover, both RH30 and
CW9019 ARMS lines home to the bone marrow in lethally
irradiated mice, while the ERMS cell lines RD, SMS-CTR,
and RH18 do not [99]. Conversely, siRNA against PAX3-
FOXO1 prevents migration of cells in wound-healing
assays of RH30 cells in response to HGF. In addition to a
Table 1 PAX3-FOXO1 target genes in ARMS
Gene Description Regulation References PF target
ABAT 4-Aminobutyrate aminotransferase; Up [72-74] Yes
ACTC Actin, alpha, cardiac muscle 1 Up [5,75] Yes
ADAM10 A disintegrin and metalloproteinase domain 10 Up [73] [72] Yes
ADRA2A Alpha-2 adrenergic receptor subtype C10 Up [72,74,76] Yes
ADRA2C Alpha-2 adrenergic receptor subtype C4 Up [22,74,76] Yes
ALK ALK tyrosine kinase receptor, anaplastic lymphoma kinase Ki-1 Up [22,72,74,76,77] Yes
ANK2 Ankyrin 2 Up [73,74,76] Yes
ASS Argininosuccinate synthase Up [73,74,78] ?
ASTN2 Astrotactin 2 Up [72,76] Yes
BIN1 Bridging integrator 1 Down [72,79] Yes
BMP5 Bone morphogenic protein 5 Up [72-74,76] Yes
C10ORF6 Family with sequence similarity 178, member A Up [75,76] Yes
CCND1 Cyclin D1 Down [75] [79] ?
CD9 CD9 molecule/Tetraspanin-29 Up [73,76] Yes
CDH3 Cadherin 3, type 1, P-cadherin (placental) Up [72,76,80] Yes
CHD7 Chromodomain helicase DNA-binding protein 7 Up [76,81] Yes
CKM Creatine kinase M chain, muscle Up [5,79] Yes
CNR1 Cannabinoid receptor 1 Up [22,72,74,82-84] Yes
COL18A1 Collagen type 18 α 1 Up [73,74] ?
CXCR4 C-X-C chemokine receptor type 4 Up [75,76,85-87] Yes
CXCR7 C-X-C chemokine receptor type 7 Down [76,87] Yes
DCX Neuronal migration protein doublecortin Up [73,74,81] ?
DES Desmin Down [72,79] Yes
DKFZP762M127 Unknown Up [73,74,81] Yes
DUSP4 Dual specificity phosphatase 4 Down [73,81] ?
DZIP3 DAZ interacting protein 3, zinc finger Up [72,74,81] Yes
ELA1 Elastase-1 Up [22,72,74] Yes
ENC1 Ectodermal-neural cortex 1 (with BTB-like domain) Up [75,76] Yes
ENO3 Enolase 3 (beta, muscle) Up [74,79] ?
EPHA4 Ephrin type-A receptor 4 Up/down [76,81,82] Yes
FGFR2 Fibroblast growth factor receptor 2 Up [72,76] Yes
FGFR4 Fibroblast growth factor receptor 4 Up [22,73,76,88,89] Yes
FLNB Filamin B, beta Down [76,82] Yes
FNBP1 Formin-binding protein 1 Down [22,75,76] ?
FOXF1 Forkhead box protein F1 Up [22,72,74,76,81] Yes
FOXO1 Forkhead box O1 Up [75,76] Yes
GADD45A Growth arrest and DNA-damage-inducible protein GADD45 alpha Up [73,76,81] Yes
GRAF GTPase regulator associated with FAK Up [22,72] Yes
GTF3C1 General transcription factor 3C Up [72,81] Yes
H19 Imprinted maternally expressed gene, untranslated mRNA Up [5,79] Yes
HDAC5 Histone deacetylase 5 Up [73,76] Yes
HUMMLC2B Myosin regulatory light chain 2, skeletal muscle isoform Down [72,73] Yes
IGF2 Insulin-like growth factor II Up [5,75] Yes
IGFBP3 IGF-binding protein 3 Down [73,81] Yes
Marshall and Grosveld Skeletal Muscle 2012, 2:25 Page 5 of 14
http://www.skeletalmusclejournal.com/content/2/1/25
Table 1 PAX3-FOXO1 target genes in ARMS (Continued)
IGFBP5 IGF-binding protein 5 Up [5] Yes
IL4R Interleukin 4 receptor Up [72,73,75,76] Yes
JAKMIP2 Janus kinase and microtubule-interacting protein 2 Up [72-74,76] Yes
KCNN3 Small conductance calcium-activated potassium channel protein 3 Up [73,74,81] Yes
KCNS3 Potassium voltage-gated channel subfamily S member 3 Up [73,74] ?
LRRFIP2 Leucine-rich repeat (in FLII) interacting protein 2 Up [72,74] Yes
MARCH3 Membrane-associated RING finger protein 3 Up [73,81] Yes
MCAM Melanoma cell adhesion molecule Up [73,81] Yes
MEG3 Maternally expressed 3 Up [73-75] ?
MN1 Meningioma (disrupted in balanced translocation) 1 Up [73,76] Yes
MET Hepatocyte growth factor receptor Up [73,76,81,90-92] Yes
MTUS2 Microtubule associated tumor suppressor candidate 2 Up [72,76] Yes
MYBPH Myosin-binding protein H Up/down [5,72,75] Yes
MYCN N-MYC proto-oncogene protein Up [72,73,76,78,81] Yes
MYH8 Myosin, heavy chain 8, skeletal muscle, perinatal Up/down [5,72] Yes
MYL1 Myosin, light chain 1, alkali; skeletal, fast Up/down [5,79] Yes
MYL4 Myosin, light chain 4, alkali; atrial, embryonic Up/down [5,72] Yes
MYOD Myoblast determination protein 1 Up [5,73,76,81] Yes
MYOG Myogenin (myogenic factor 4) Up [5,90] Yes
NEBL Nebulette Up/down [72,73,76,81] Yes
NELL1 NEL-like protein 1 Up [22,72-74,76] Yes
NHLH1 Nescient helix loop helix 1 Up [22,76] Yes
NPTX2 Neuronal pentraxin II Down [76,81] Yes
NRCAM Neuronal cell adhesion molecule Up [72-74] Yes
OLIG2 Oligodendrocyte transcription factor 2 Up [22,74] ?
PALMD Palmdelphin Down [72,76] Yes
PBK PDZ-binding kinase Up [73,76] Yes
PCDH7 Protocadherin 7 Up [76,82] Yes
PDZRN3 PDZ domain containing ring finger 3 Up [74,76] Yes
PGBD5 PiggyBac transposable element-derived protein 5 Up [22,72,74] Yes
PHF17 PHD finger protein 17 Up [74,76] Yes
PIPOX Pipecolic acid oxidase Up [22,72,74,76] Yes
PKP1 Plakophilin 1 (ectodermal dysplasia/skin fragility syndrome) Up [72,76] Yes
PLAG1 Pleiomorphic adenoma gene 1 protein Down [75,81] Yes
PLK2 Polo-like kinase 2 Down [73,76] Yes
PODXL Podocalyxin-like protein 1 Up [22,74,76] Yes
POU4F1 Brain-specific homeobox/POU domain protein 3A Up [72,73,76] Yes
PPARGC1A Peroxisome proliferator-activated receptor gamma, coactivator 1 alpha Up [22,76] Yes
PRKAR2B Protein kinase, cAMP-dependent, regulatory, type II, beta Up [73,81,82] Yes
PRKCA Protein kinase C, alpha Up [73,76] Yes
PSEN2 Presenilin 2 (Alzheimer’s disease 4) Up [73,74] ?
PTHLT Parathyroid hormone-like hormone Up [76,82] Yes
QDPR Quinoid dihydropteridine reductase Up [74,81] Yes
RASSF4 Ras association (RalGDS/AF-6) domain family 4 Up [72,74,76] Yes
RRP22 Ras-like protein family member 10A, on chm 22 Up [73,74] ?
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Table 1 PAX3-FOXO1 target genes in ARMS (Continued)
RYR1 Skeletal muscle-type ryanodine receptor Up [5,74] Yes
RYR3 Brain-type ryanodine receptor Up [74,76,81] Yes
SLC24A3 Solute carrier family 24 (sodium/potassium/calcium exchanger), member 3 Up [74,76] Yes
SIX1 SIX homeobox 1 Up [5,75] Yes
SOX14 SRY (sex determining region Y)-box 14 Up [22,76] Yes
STX11 Syntaxin 11 Up [76,82] Yes
SULF1 Sulfatase 1 Up [73,76] Yes
SVIL Supervillin Down [72,76] Yes
TCF712 Transcription factor 7-like 2 (T-cell specific, HMG-box) Up [73,81] Yes
TGFB1 Transforming growth factor, beta 1 Up [5,76] Yes
TFAP2B Transcription factor AP-2 beta Up [22,72] Yes
TIAF1 TGF-beta-1-induced antiapoptotic factor 1 Up [73,74] ?
TM4SF10 Transmembrane 4 superfamily member 10 Up [73,81] Yes
TNFAIP3 Tumor necrosis factor, alpha-induced protein 3 Up [73,76] Yes
TNNC2 Troponin C type 2 (fast) Up/down [5,72,73,79] Yes
TNNI2 Troponin I type 2 (skeletal, fast) Up/down [5,72] Yes
TNNT2 Troponin T type 2 (cardiac) Up [5,79] Yes
TNNT3 Troponin T type 3 (skeletal, fast) Down [72,79] Yes
TRAM2 Translocation-associated membrane protein 2 Up [73,76] Yes
TSC22D2 TSC22 domain family, member 2 Up [74,76] Yes
UBE2G2 Ubiquitin-conjugating enzyme E2G 2 (UBC7 homolog, yeast) Up [22,76] Yes
WSCD1 WSC domain-containing protein 1 Up [22,74] ?
WVA5A Von Willebrand factor A domain containing 5A Up [72-74] Yes
Summary of genes found to be differentially regulated in more than one reference in ARMS tumors and/or cell lines, or by PAX3-FOXO1 overexpression, in various
cell types. Gene name and description are indicated and also the relative expression in ARMS or PAX3-FOXO1. Also indicated is whether the study indicates that
these genes are downstream of PAX3-FOXO1 expression. Genes indicated in bold will be further discussed.
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MET by shRNA in ERMS and ARMS inhibits cell prolifera-
tion and induces apoptosis. Moreover, shRNA-mediated
knockdown of MET inhibits anchorage-independent
growth of ARMS and ERMS, and mutant MET-expressing
MEFS prevent PAX3-FKHR transformation [91]. Consist-
ent with METas a PAX3-FOXO1 target, high MET expres-
sion in RMS correlates with ARMS histology, advanced
disease at diagnosis and bone marrow involvement [100].
CXCR4 is normally expressed in satellite cells within
skeletal muscle and is used as a marker of mononucleated
cells capable of differentiating into myofibers [101].
CXCR4 is a cell surface receptor; it binds and mediates
the signaling of stromal-derived factor-1 (SDF-1) and
induces cell chemotaxis [102]. SDF-1 can induce migra-
tion and chemotactic invasion in ARMS cell lines, but not
ERMS cell lines [85], and this migration can be inhibited
by SDF-1-neutralizing antibody or the CXCR4 inhibitor
AMD3100 [103]. Moreover, expression of CXCR4 and
MET in ARMS lines appears to synergize to induce the
migration of cells toward bone marrow-derived fibroblast
conditioned media in vitro. Inhibition of each receptorreduces migration, and combined inhibition reveals syner-
gism between these receptors [99]. SDF-1 can also induce
proliferation of the ARMS cell line, RH30 [103]. Consist-
ent with CXCR4 expression being downstream of PAX3-
FOXO1 transgene expression, CXCR4 expression in RMS
correlates with the ARMS histology, unfavorable primary
site, advanced disease at diagnosis and bone marrow in-
volvement [100].
Other genes have been further confirmed as down-
stream genes of PAX3-FOXO1. Cannabinoid receptor 1
(CNR1) is specifically upregulated at both the mRNA
and protein level in fusion-positive ARMS cells [74].
CNR1 is normally highly expressed in brain [104] but is
also expressed in skeletal muscle at levels detectable by
RT-PCR [105]. CNR1 has been confirmed, using ChIP
analysis, as a direct target of both PAX3 and PAX3-
FOXO1 transcriptional activity [82]. Furthermore, the
homeodomain of PAX3-FOXO1 appears to be the im-
portant domain for the regulation of CNR1 expression
[72]. CNR1 has been proposed to be a potential drug
target in ARMS. Treatment with CNR1 agonists can in-
duce apoptosis in some ARMS cell lines [83]. In addition,
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sity for PAX3-FOXO1 expressing mouse myoblast invasive-
ness and lung metastasis formation. Moreover, treatment
with an inverse agonist to CNR1 can abrogate in vitro inva-
sion and in vivo lung metastasis formation [84]. Thus,
CNR1 may represent a viable therapeutic target specific for
the increased metastatic capacity of PAX3-FOXO1 expres-
sing ARMS.
Transcription factor AP2β (TFAP2B) has been shown to
be a downstream target of PAX3-FOXO1 and appears to
require the paired domain of PAX3-FOXO1 to be induced.
TFAP2B promoter expression is induced by PAX3, which
has been shown to bind to the TFAP2B promoter by ChIP
analysis. siRNA targeting TFAP2B introduced into PAX3-
FKHR-positive ARMS induces apoptosis, indicating that
TFAP2B can mediate cell survival in ARMS, downstream
of PAX3-FOXO1 [72].
FGFR4 has been identified as a direct transcriptional tar-
get of PAX3 and PAX3-FOXO1, which bind to a down-
stream enhancer region [76,106]. Accordingly, FGFR4 is
significantly upregulated by PAX3-FOXO1 expression
[22,73,76,88,89,107]. However, upregulation of FGFR4
downstream of PAX3-FOXO1 in primary myoblasts does
not appear to act as an effector of PAX3-FOXO1-mediated
myoblast transformation given that wild-type FGFR4 upre-
gulation is not required for PAX3-FOXO1-induced prolif-
eration, transformation, invasion or inhibition of myogenic
differentiation [89]. However, knockdown of FGFR4 in
RMS cell lines does show a reduction in cell proliferation
and an increase in apoptosis, suggesting that at later stages
of ARMS tumorigenesis FGFR4 overexpression may inter-
act with other unknown genetic lesions within these cell
lines to induce pro-survival and proliferation effects [107].
It is interesting to note however that kinase domain-
activating mutations in FGFR4 have been identified in 7.5%
of RMS, including fusion-positive ARMS [108], and can
contribute to myoblast growth advantage and transform-
ation [89]. Thus, FGFR4-activating mutations likely repre-
sent cooperating mutations in RMS and upregulation of
FGFR4 in fusion-positive ARMS would enhance this effect.
The CDH3/P-cadherin gene has been identified as a dir-
ect transcriptional target of PAX3/7-FOXO1 [72,76,80]. P-
cadherin expression in the C2C12 myoblast cell line inhi-
bits myogenic differentiation and maintains a proliferative
state through maintaining cyclin D1 expression. This in
turn results in transformation of C2C12 cells, allowing col-
ony formation in soft agar. Additionally, P-cadherin expres-
sion resulted in enhanced cell motility, as well as cadherin
switching, a hallmark of epithelial to mesenchymal transi-
tion and metastatic progression [80].
In vitro models of ARMS
Many different cell lines have been derived from human
ARMS tumors; these are regularly used to investigatethe biology of ARMS. These include ARMS cell lines
derived from human tumors in the laboratory of Dr. Peter
Houghton: RH3, RH4, RH10, RH28, RH30 and RH41, all of
which express the PAX3-FOXO1 fusion protein
[13,109,110] and have been widely used in the field. In
addition, the NCI-supported Pediatric Preclinical Testing
Program (PPTP) uses RH10, RH28, RH30, RH30R, RH41
and RH65 subcutaneous xenograft tumors to test drug effi-
cacy in a well-characterized preclinical model of many
pediatric cancers [111-113].
Other in vitro models that have been used involve the
introduction of the PAX3/7-FOXO1 fusion proteins into
both myogenic and non-myogenic cell lines including fibro-
blast cell lines, ERMS cell lines, MEFs, mesenchymal stem
cells (MSC), normal or immortalized human or mouse
myogenic cells and even an osteosarcoma cell line
[5,81,82,91,114-119]. Given that the cell of origin for ARMS
has yet to be identified, perhaps this variation in model cell
lines is prudent. However, it is likely that ARMS and ERMS
tumors are derived from a mesenchymal cell likely of the
the myogenic lineage because of skeletal muscle lineage-
specific gene expression seen in these tumors [7].
Conversely, some studies have used endogenous
PAX3-FOXO1 in ARMS cell lines to determine the tran-
scriptional targets of this fusion protein within the
ARMS tumor cell context. Both Kikuchi et al. [90] and
Ebauer et al. [72] used siRNA specifically targeting
PAX3-FOXO1 or both PAX3 and PAX3-FOXO1
sequences, respectively. Inhibition of PAX3-FOXO1
expression reduced cell proliferation and motility and
allowed some myogenic differentiation [90]. In addition,
comparative gene expression studies were performed
identifying over 100 PAX3-FOXO1 gene targets. Cao
et al. [76] performed ChIP sequencing studies using a
PAX3-FOXO1-specific antibody and were able to iden-
tify 1,463 putative PAX3-FOXO1-binding sites in the
human genome. Furthermore, PAX3-FOXO1-binding
sites adjacent to MyoD, FGFR4 and IGF1R were verified
as transcriptionally regulated by PAX3-FOXO1.
In vivo models of ARMS
Many different transgenic and knock-in animal models
have been attempted to recapitulate ARMS tumor for-
mation in vivo. Several of these models have attempted
to constitutively express PAX3/7-FOXO1 fusion proteins
in the skeletal muscle lineage during development, only
to result in developmental defects and not tumor forma-
tion [120-123]. Transgenic mice expressing PAX3-
FOXO1 under the control of the PAX3 promoter and
enhancer regions resulted in expression of PAX3-
FOXO1 in the dorsal neural tube and lateral dermomyo-
tome. PAX3-FOXO1 expression in this context appeared
to interfere with normal PAX3 developmental functions
including neural tube and neural crest abnormalities
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majority of defects appeared to be in neural develop-
ment, though defects were seen in hind limb skeletal
muscle; however, no tumors developed [121,122].
Lagutina et al. [120] developed a model where PAX3-
FOXO1 was knocked into the PAX3 locus. This knock-in
locus expressed low amounts of PAX3-FOXO1, which in
heterozygous pups was sufficient to result in developmental
defects in the heart and diaphragm, leading to congestive
heart failure and perinatal death, as well as malformations
of some hypaxial muscles. However, neither chimeric adults
nor their newborn heterozygous pups developed malignan-
cies. It was hypothesized that PAX3-FOXO1 expression
from the PAX3 control sequences was insufficient to cause
ARMS formation, and downstream regions of the FOXO1
locus may be required to induce sufficient PAX3-FOXO1
expression to induce tumor development.
A PAX7-FOXO1 model of ARMS was also attempted
in Drosophila [123]. Expression of UAS-hPAX7-FOXO1,Figure 2 Review summary: Fusion gene regulated genes contributing to
unknown cell of origin from the mesodermal lineage that may be skeletal
and may also express Myf6. A gene fusion event resulting in a PAX3/7 DNA
domain occurs. This fusion transcription factor is capable of inducing a gro
development in conjunction with other genetic lesions.under control of myosin heavy-chain Gal4, also resulted
in developmental defects in the fly, evidenced by disor-
ganized myogenic patterning. Though nothing resem-
bling tumor formation was seen, this group did note
dissemination and infiltration of non-native tissue by
PAX7-FOXO1 expressing mononucleated cells, indicat-
ing an increase in invasive capacity of these cells.
Keller et al. [47] used a conditional PAX3-FOXO1
knock-in into the PAX3 locus, and Myf6-driven Cre ex-
pression. This allowed, upon Cre recombination, expres-
sion of PAX3-FOXO1 driven by the PAX3 promoter and
3’ FOXO1 genomic sequences that potentially contain cis-
regulatory elements, a region absent from previous PAX3
knock-in strategies. This was the first animal model that
successfully recapitulated the formation of ARMS, though
at the low frequency of approximately 0.4% (1/228) and
with latency of over 1 year (383 days). However, this fre-
quency was greatly enhanced, and latency greatly reduced,
in homozygote PAX3P3Fa/P3Fa mice also lacking Trp53 oralveolar rhabdomyosarcoma. Rhabdomyosarcoma develops from an
muscle specified. This cell likely expresses both PAX3/7 and FOXO1
-binding domain fused to a more potent transcriptional activation
up of PAX3-FOXO1-regulated genes that contribute to ARMS
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oped in this conditional PAX3-FOXO1 knock-in
model with a Pax7-CreER and M-Cre (Pax3 hypaxial
muscle enhancer) also lacking functional Trp53
[124]. Moreover, histologically diagnosed fusion-
negative ARMS tumors have been found to develop
in conditional Ptch1+/− Trp53−/− mice when Cre is
expressed from Pax7-CreER. The latency and incidence of
ARMS tumor development in these different models have
yet to be compared.
Clearly the problems that have arisen during the devel-
opment of an animal model for ARMS indicate that the
timing and the cell lineage targeted for PAX3-FOXO1
expression are very important for the development of
ARMS tumor formation and for avoiding developmental
defects. In a review [125] following the publication of
the animal model [47], Keller et al. discuss the possibil-
ities for the cell of origin for ARMS; because Keller
et al. achieved the formation of ARMS tumors in their
mouse model using Myf6-Cre-driven conditional PAX3-
FOXO1, and Myf6 is usually expressed in differentiating
skeletal muscle myotubes, they propose a potential de-
differentiation mechanism for ARMS development.
However, the formation of a fusion gene such as PAX3-
FOXO1 suggests that the cell of origin for ARMS should
express both PAX3 and FOXO1 at the time that the
translocation occurs, given that open chromatin is likely
required for these two genomically distinct regions to
translocate. Anecdotal evidence for this includes that the
genome translocations that occur in many different can-
cer types occur between genes that are expressed in the
cell type of origin. A recent study by Osborne et al.
[126] showed that the MYC and IGH genes, which are
involved in a chromosomal translocation common in
Burkitt lymphoma, are colocalized at the same transcrip-
tion factories more often in activated B-cells, the origin-
ating cell of Burkitt lymphoma, than resting B cells. This
colocalization at the same transcription factory allows
for close proximity of these gene loci in euchromatin,
providing the circumstances where these genes would be
in close association, facilitating the specific translocation
event. PAX3 is rapidly downregulated upon myoblast
differentiation, so it would be unlikely that the PAX3
loci would be expressed in a nascent myotube expressing
Myf6, making it difficult to understand how transloca-
tion could occur in nascent myotubes and therefore cast
some doubt on whether the dedifferentiation model is
feasible. However, it is possible that Myf6 expression
does rarely occur in a small subset of undifferentiated
myogenic cells in conjunction with PAX3. This could
allow for this model to produce ARMS tumors and ac-
count for the low frequency at which these tumors are
seen as well as the requirement for homozygous PAX3-
FOXO1 knock-in alleles [47].From these animal models it is apparent that the tim-
ing of PAX3-FOXO1 expression is critical for ARMS
development. Too early and widespread expression of
PAX3-FOXO1 expression can result in developmental
defects and no apparent tumor development [120-123],
whereas later expression of PAX3-FOXO1, via a Myf6-
driven Cre recombinase, does cause disease, though at a
low frequency [47]. Perhaps inducible expression, driven
by various myogenic genes with carefully characterized
expression profiling, would result in an increased fre-
quency of disease and help to narrow down the exact
stage in which PAX3-FOXO1 expression drives ARMS
tumorigenesis. Nevertheless, the cell of origin for
ARMS is yet to be identified, and animal models of
ARMS will no doubt play an important role in its
identification.
Conclusion
To date, numerous factors (outlined in Figure 2) have
been identified that contribute to ARMS tumor develop-
ment and its aggressive clinical phenotype. These consist
of both PAX3/7-FOXO1 target genes, such as N-MYC,
IGF2, MET, CXCR4, CNR1, TFAP2B, FGFR4 and P-cad-
herin, and PAX3/7-FOXO1 cooperating factors, such as
the abrogation of the p53 pathway, IGF2 deregulation,
N-MYC and miR17-92 amplification, and IRIZIO
expression. Future ARMS research will continue to dis-
cover the mechanisms by which ARMS tumorigenesis
occurs. This will involve the identification of more PAX3-
FOXO1 target and cooperating genes; more importantly,
the mechanisms by which these genes contribute to
tumorigenesis will be elucidated. It is critical that we
develop a mechanistic understanding of how these factors
contribute and interact to perpetrate ARMS tumo-
rigenesis. This will allow new opportunities to develop
specifically targeted therapies for this aggressive pediatric
disease.
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